Relmada Therapeutics

(NASDAQ) RLMD

Current Price$7.36

Market Cap$759.39M

Since IPO (2014)-88%

5 Year-81%

1 Year+1,927%

1 Month+13%

Relmada Therapeutics Financials at a Glance

Market Cap

$759.39M

Revenue (TTM)

$0.00

Net Income (TTM)

$57.39M

EPS (TTM)

$-1.47

P/E Ratio

-4.93

Dividend

$0.00

Beta (Volatility)

0.01 (Low)

Dividend

$0.00

Beta (Volatility)

0.01 (Low)

Price

$7.36

Volume

25,469

Open

$7.20

Price

$7.36

Volume

25,469

Open

$7.20

Previous Close

$7.36

Daily Range

$7.11 - $7.37

52-Week Range

$0.27 - $7.94

Dividend

$0.00

Beta (Volatility)

0.01 (Low)

Price

$7.36

Volume

25,469

Open

$7.20

Previous Close

$7.36

Daily Range

$7.11 - $7.37

52-Week Range

$0.27 - $7.94

RLMD News

Here's Why Relmada Therapeutics Stock Popped Today

Cory RenauerJul 27, 2021

Woman scientist in lab holding up test tube

Is It Too Late to Buy These 3 Pharmaceutical Stocks?

James HalleyJul 7, 2020

Could Opioids Treat Depression? This Biotech Plans to Find Out

Zhiyuan SunMay 19, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Relmada Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Sergio Traversa, PhD, MBA

Website

www.relmada.com

Headquarters

Coral Gables, FL 33134, US

RLMD Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-94%

Return on Capital

-67%

Return on Assets

-61%

Earnings Yield

-20.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$759.39M

Shares Outstanding

104.89M

Volume

25.47K

Avg. Volume

1.78M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$59.10M

EBITDA

$59.10M

Operating Cash Flow

$45.79M

Capital Expenditure

$0.00

Free Cash Flow

$45.79M

Cash & ST Invst.

$93.01M

Total Debt

$0.00

Relmada Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$759.39M

N/A

Market Cap/Employee

$44.67M

N/A

Employees

N/A

Net Income

$19.87M

-6.5%

EBITDA

$20.57M

N/A

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$93.01M

+107.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-61.05%

N/A

Return on Invested Capital

-67.49%

N/A

Free Cash Flow

$31.19M

+454.5%

Operating Cash Flow

$31.19M

+454.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VXRTVaxart, Inc.

VXRTVaxart, Inc.$0.75-0.65%

RPTXRepare Therapeutics Inc.

RPTXRepare Therapeutics Inc.$2.65+0.00%

IMUXImmunic, Inc.

IMUXImmunic, Inc.$10.03-6.70%

PMVPPMV Pharmaceuticals, Inc.

PMVPPMV Pharmaceuticals, Inc.$1.39-2.11%

ACETAdicet Bio, Inc.

ACETAdicet Bio, Inc.$7.63-0.52%

FBIOFortress Biotech, Inc.

FBIOFortress Biotech, Inc.$2.22-0.89%

TCRXTScan Therapeutics, Inc.

TCRXTScan Therapeutics, Inc.$1.15-8.73%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.53-0.15%

NOKNokia

NOKNokia$12.46+0.10%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.14+0.04%

KALVKalVista Pharmaceuticals

KALVKalVista Pharmaceuticals$26.67+0.39%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$61.86+0.02%

POETPoet Technologies

POETPoet Technologies$6.60-0.18%

ONDSOndas

ONDSOndas$9.49-0.09%

Questions About RLMD

What is the current price of Relmada Therapeutics?

Relmada Therapeutics is trading at $7.36 per share.

What is the 52-week range for Relmada Therapeutics?

Over the past 52 weeks, Relmada Therapeutics has traded between $0.27 and $7.94.

How much debt does Relmada Therapeutics have?

As of the most recent reporting period, Relmada Therapeutics reported total debt of N/A.

How much cash does Relmada Therapeutics have on hand?

Relmada Therapeutics reported $3.50M in cash and cash equivalents in its most recent financial results.

What is Relmada Therapeutics’s dividend yield?

Relmada Therapeutics does not currently have a dividend yield.

Relmada Therapeutics

Relmada Therapeutics Financials at a Glance

RLMD News

Here's Why Relmada Therapeutics Stock Popped Today

Is It Too Late to Buy These 3 Pharmaceutical Stocks?

Could Opioids Treat Depression? This Biotech Plans to Find Out

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Relmada Therapeutics

RLMD Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Relmada Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RLMD

What is the current price of Relmada Therapeutics?

What is the 52-week range for Relmada Therapeutics?

How much debt does Relmada Therapeutics have?

How much cash does Relmada Therapeutics have on hand?

What is Relmada Therapeutics’s dividend yield?

Premium Investing Services